Prognostic value of unrelated atypical serum immunofixation patterns during Multiple Myeloma therapy

Journal of Hematology & Oncology

Fernanda Trigo⁴  João T Guimarães²  Nuno Couto¹  Renata Ramalho³  Rui Bergantim⁴  Cristina Guimarães³ 

[1] Department of Medical Oncology, Portuguese Institute of Oncology Francisco Gentil, Porto, Portugal;Department of Clinical Pathology, Centro Hospitalar São João, Porto, Portugal, Portugal;Department of Immunology, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200, Porto, Portugal;Department of Hematology, Centro Hospitalar São João, Porto, Portugal

关键词: Serum immunofixation patterns;    Marker of prognosis;    Autologous stem cell transplantation;    Multiple myeloma;   

Others  :  822395
DOI  :  10.1186/1756-8722-5-33

 received in 2012-03-30, accepted in 2012-04-23,  发布年份 2012

【 摘 要 】

Autologous stem cell transplantation (ASCT) is the gold standard therapy for suitable multiple myeloma (MM) patients after induction with high dose therapy. To date, the evidence of a reliable marker of prognosis in these cases remains scarce. Our aim was to evaluate appearance of unrelated atypical serum immunofixation patterns (ASIPs) as a marker of prognosis in MM patients submitted to ASCT. We retrospectively analysed data from 65 patients. Interestingly, we observed that presence of ASIPs was associated with longer progression-free survival and longer overall survival. Our results suggested that presence of ASIPs could be a novel marker of good prognosis in MM patients submitted to ASCT.

【 授权许可】

   
2012 Guimaraes et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC: Focus on multiple myeloma. Cancer Cell 2004, 6:439-444.
• [2]Hall SL, Tate J, Gill D, Mollee P: Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation. Clin Biochem Rev 2009, 30:113-118.
• [3]Hovenga S, de Wolf JT, Guikema JE, Klip H, Smit JW, Smit Sibinga CT, Bos NA, Vellenga E: Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Bone Marrow Transplant 2000, 25:723-728.
• [4]Zent CS, Wilson CS, Tricot G, Jagannath S, Siegel D, Desikan KR, Munshi N, Bracy D, Barlogie B, Butch AW: Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood 1998, 91:3518-3523.
• [5]Mark T, Jayabalan D, Coleman M, Pearse RN, Wang YL, Lent R, Christos PJ, Lee JW, Agrawal YP, Matthew S, et al.: Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol 2008, 143:654-660.
• [6]Alejandre ME, Madalena LB, Pavlovsky MA, Facio ML, Corrado C, Milone G, Bresciani PD, Fraind SA, Pavlovsky S, Pizzolato MA: Oligoclonal bands and immunoglobulin isotype switch during monitoring of patients with multiple myeloma and autologous hematopoietic cell transplantation: a 16-year experience. Clin Chem Lab Med 2010, 48:727-731.
• [7]Wadhera RK, Kyle RA, Larson DR, Dispenzieri A, Kumar S, Lazarus HM, Rajkumar SV: Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood 2011, 118:2985-2987.